Asset Details
Do you wish to reserve the book?
Cost-utility and budget impact analysis of desmopressin for treating monosymptomatic nocturnal enuresis in Thai children
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cost-utility and budget impact analysis of desmopressin for treating monosymptomatic nocturnal enuresis in Thai children
Do you wish to request the book?
Cost-utility and budget impact analysis of desmopressin for treating monosymptomatic nocturnal enuresis in Thai children
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cost-utility and budget impact analysis of desmopressin for treating monosymptomatic nocturnal enuresis in Thai children
2025
Overview
Monosymptomatic nocturnal enuresis (MNE) imposes a notable clinical and psychosocial burden, yet no economic evaluations have been conducted in Thailand. This study conducted the cost-utility analysis (CUA) and budget impact analysis (BIA) of desmopressin acetate compared with imipramine and no treatment in children aged ≥ 7 years with MNE who have not responded to behavioural management and not responded, or expected not to respond, to alarm therapy. A CUA was conducted from a partial societal perspective, and a BIA was undertaken from a payer perspective. Model parameters were source from published evidence and expert opinion. Desmopressin yielded the highest quality-adjusted life years (QALYs) (9.77) and costs ($740.54). The incremental cost-effectiveness ratios were $2,385/QALY versus no treatment and $2,226/QALY versus imipramine, both below Thailand’s willingness-to-pay threshold ($4,733.73/QALY). Probabilistic sensitivity analysis indicated a 73.5–74.0% probability of cost-effectiveness. The five-year budget impact of introducing desmopressin was estimated at $26.998 million. These findings suggest that desmopressin may represent a cost-effective option for managing MNE, although its adoption would careful consideration of budgetary implications. The results provide context-specific evidence to inform policy deliberations in Thailand and may offer insights for other low- and middle-income countries.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
